The University of Chicago Header Logo

Stanley Liauw

Concepts (302)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Prostatic Neoplasms
66
2023
1721
10.190
Why?
Radiotherapy, Intensity-Modulated
21
2020
173
3.810
Why?
Androgen Antagonists
18
2022
144
3.320
Why?
Radiation Injuries
9
2019
156
3.300
Why?
Prostatectomy
24
2022
471
2.960
Why?
Adenocarcinoma
17
2019
1169
2.840
Why?
Prostate-Specific Antigen
24
2022
353
2.780
Why?
Chemoradiotherapy
7
2021
301
2.710
Why?
Radiotherapy Dosage
28
2023
468
2.570
Why?
Neoplasm Recurrence, Local
19
2022
1313
2.240
Why?
Anus Neoplasms
4
2021
30
2.070
Why?
Radiotherapy, Conformal
7
2016
83
1.970
Why?
Salvage Therapy
16
2022
233
1.930
Why?
Urinary Incontinence
4
2016
206
1.670
Why?
Radiotherapy, Adjuvant
11
2018
292
1.660
Why?
Anticoagulants
5
2022
407
1.650
Why?
Quality of Life
7
2022
1587
1.620
Why?
Aged
61
2024
18407
1.600
Why?
Male
92
2023
40995
1.570
Why?
Aged, 80 and over
34
2020
6511
1.500
Why?
Middle Aged
64
2020
25027
1.460
Why?
Urinary Bladder Neoplasms
5
2024
383
1.370
Why?
Prostate
7
2023
378
1.310
Why?
Radiotherapy, Image-Guided
5
2020
56
1.300
Why?
Humans
110
2024
86656
1.230
Why?
Brachytherapy
8
2019
119
1.220
Why?
Head and Neck Neoplasms
6
2021
1052
1.200
Why?
Antineoplastic Agents, Hormonal
4
2021
150
1.200
Why?
Neoplasm Staging
22
2020
1938
1.170
Why?
Papillomavirus Infections
2
2021
239
1.150
Why?
Follow-Up Studies
20
2022
3639
1.090
Why?
Radiotherapy
9
2019
328
1.070
Why?
Urogenital System
4
2014
9
1.060
Why?
Fluorouracil
7
2017
556
1.050
Why?
Radiosurgery
4
2019
272
1.050
Why?
Capecitabine
5
2024
96
1.020
Why?
Platelet Aggregation Inhibitors
3
2022
134
0.960
Why?
Carcinoma, Hepatocellular
2
2022
386
0.960
Why?
Rectal Neoplasms
4
2016
116
0.920
Why?
Liver Neoplasms
3
2022
736
0.910
Why?
Rectal Diseases
3
2013
24
0.900
Why?
Combined Modality Therapy
20
2024
1686
0.880
Why?
Antimetabolites, Antineoplastic
2
2018
236
0.870
Why?
Antineoplastic Combined Chemotherapy Protocols
7
2018
2438
0.860
Why?
Cooperative Behavior
1
2023
176
0.860
Why?
Pancreatic Neoplasms
4
2017
645
0.820
Why?
Aspirin
2
2013
155
0.800
Why?
Radiation Oncology
4
2021
119
0.800
Why?
Treatment Outcome
24
2020
7982
0.800
Why?
Gastrointestinal Tract
3
2013
191
0.790
Why?
Patient Care Team
1
2023
280
0.790
Why?
Risk Assessment
12
2020
2261
0.760
Why?
Urinary Bladder
3
2024
245
0.750
Why?
Chemoradiotherapy, Adjuvant
3
2017
35
0.750
Why?
Hypersensitivity
1
2022
154
0.740
Why?
Carcinoma, Squamous Cell
5
2018
1077
0.720
Why?
Oropharyngeal Neoplasms
1
2021
118
0.710
Why?
Magnetic Resonance Imaging
3
2018
3366
0.700
Why?
Retrospective Studies
24
2021
8476
0.700
Why?
Long Term Adverse Effects
1
2019
6
0.700
Why?
Cystectomy
3
2024
102
0.700
Why?
Fiducial Markers
2
2020
7
0.690
Why?
Rectum
4
2014
146
0.690
Why?
Analysis of Variance
9
2015
911
0.680
Why?
Neoplasm Grading
9
2022
357
0.670
Why?
Hematuria
3
2022
48
0.670
Why?
Lymph Node Excision
4
2017
217
0.670
Why?
Prognosis
15
2020
3681
0.650
Why?
Adult
32
2020
25648
0.630
Why?
Tomography, X-Ray Computed
6
2020
2585
0.620
Why?
Urologic Neoplasms
1
2018
77
0.620
Why?
Time Factors
15
2020
5215
0.600
Why?
Organs at Risk
3
2020
41
0.570
Why?
Leukopenia
1
2016
65
0.570
Why?
Organ Transplantation
1
2020
265
0.570
Why?
Pelvic Bones
1
2016
43
0.560
Why?
Prospective Studies
8
2022
4212
0.550
Why?
Chemotherapy, Adjuvant
6
2015
468
0.550
Why?
Risk Factors
10
2020
5416
0.540
Why?
Biomarkers, Tumor
3
2012
1464
0.530
Why?
Thrombocytopenia
1
2016
183
0.530
Why?
Cohort Studies
8
2022
2765
0.520
Why?
Immunosuppressive Agents
1
2020
977
0.510
Why?
Bone Marrow
1
2016
435
0.510
Why?
Sexuality
1
2014
40
0.500
Why?
Tumor Burden
5
2019
290
0.490
Why?
Multivariate Analysis
8
2017
999
0.480
Why?
Survival Rate
9
2019
1864
0.460
Why?
Gastrointestinal Hemorrhage
2
2013
230
0.450
Why?
Urinary Retention
2
2010
39
0.450
Why?
Transurethral Resection of Prostate
2
2010
9
0.450
Why?
Antineoplastic Agents
7
2019
2360
0.440
Why?
Hospitalization
1
2018
851
0.440
Why?
CA-19-9 Antigen
1
2012
11
0.440
Why?
SEER Program
6
2020
190
0.440
Why?
Herpes Zoster
1
2013
78
0.430
Why?
Postoperative Complications
2
2020
2204
0.430
Why?
Neoadjuvant Therapy
2
2012
318
0.430
Why?
Chemoprevention
1
2012
92
0.420
Why?
Carcinoembryonic Antigen
1
2012
41
0.420
Why?
Portal Vein
1
2012
119
0.420
Why?
Kaplan-Meier Estimate
8
2017
861
0.410
Why?
Lymphatic Metastasis
5
2017
486
0.400
Why?
Diabetes Complications
1
2013
207
0.400
Why?
Risk
4
2020
674
0.400
Why?
Radioimmunodetection
2
2008
13
0.400
Why?
Deoxycytidine
2
2012
237
0.390
Why?
Female
25
2022
44566
0.380
Why?
Prostatism
1
2010
5
0.380
Why?
Lymph Nodes
3
2020
533
0.370
Why?
Gastrointestinal Neoplasms
3
2021
106
0.370
Why?
Urination Disorders
1
2010
50
0.370
Why?
Body Burden
1
2009
9
0.360
Why?
Withholding Treatment
1
2010
112
0.350
Why?
Venous Thrombosis
1
2012
243
0.350
Why?
Practice Guidelines as Topic
1
2016
1037
0.350
Why?
Smoking
1
2013
609
0.340
Why?
Dose-Response Relationship, Radiation
4
2016
188
0.340
Why?
Survival Analysis
9
2019
1540
0.330
Why?
Models, Statistical
1
2012
575
0.330
Why?
Leucovorin
3
2017
218
0.330
Why?
Comorbidity
3
2021
945
0.320
Why?
Carcinoma, Renal Cell
3
2019
424
0.310
Why?
Hemorrhage
1
2009
267
0.300
Why?
Ganglioglioma
1
2006
4
0.290
Why?
Disease Progression
3
2020
1534
0.290
Why?
Radiotherapy Planning, Computer-Assisted
3
2020
176
0.290
Why?
Kidney Neoplasms
3
2019
619
0.290
Why?
Treatment Failure
4
2016
286
0.280
Why?
Testicular Neoplasms
2
2019
105
0.280
Why?
Disease-Free Survival
7
2014
1204
0.280
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2010
378
0.270
Why?
Abdomen
1
2006
120
0.270
Why?
Neoplasms, Radiation-Induced
1
2006
109
0.270
Why?
Postoperative Period
3
2015
302
0.270
Why?
Carcinoma
2
2012
436
0.270
Why?
United States
7
2021
6674
0.270
Why?
Proportional Hazards Models
5
2017
860
0.250
Why?
Lymphoma, Non-Hodgkin
1
2006
261
0.240
Why?
Probability
3
2012
354
0.240
Why?
Urethral Neoplasms
2
2018
10
0.240
Why?
Neoplasms, Second Primary
1
2006
252
0.230
Why?
Motion
1
2023
85
0.230
Why?
Neoplasm, Residual
3
2012
162
0.230
Why?
Patient Selection
3
2017
686
0.220
Why?
Propensity Score
2
2020
136
0.220
Why?
Ipilimumab
1
2022
58
0.210
Why?
Positron Emission Tomography Computed Tomography
2
2020
86
0.210
Why?
Severity of Illness Index
4
2013
1804
0.210
Why?
Contrast Media
2
2016
1073
0.210
Why?
Incidence
2
2022
1578
0.200
Why?
Radiation Oncologists
2
2021
13
0.200
Why?
Ticlopidine
2
2012
25
0.190
Why?
Neoplasm Metastasis
3
2020
1056
0.190
Why?
Radium
1
2020
7
0.190
Why?
Oncologists
1
2021
36
0.190
Why?
Brain Neoplasms
1
2006
763
0.190
Why?
Warfarin
2
2012
103
0.180
Why?
Platelet Count
1
2020
92
0.180
Why?
Internship and Residency
2
2021
1010
0.180
Why?
Radiologic Health
1
2019
2
0.180
Why?
Androgen Receptor Antagonists
1
2019
18
0.180
Why?
Sezary Syndrome
1
2019
8
0.170
Why?
Phenylthiohydantoin
1
2019
41
0.170
Why?
Mycosis Fungoides
1
2019
23
0.170
Why?
Depsipeptides
1
2019
29
0.170
Why?
Electrons
1
2019
49
0.170
Why?
Spinal Neoplasms
1
2019
48
0.170
Why?
Thoracic Vertebrae
1
2019
49
0.170
Why?
Feasibility Studies
1
2021
751
0.170
Why?
Mitomycin
2
2016
29
0.170
Why?
Colorectal Neoplasms
1
2006
938
0.160
Why?
Transplantation Conditioning
1
2020
373
0.160
Why?
Patient Reported Outcome Measures
1
2019
164
0.160
Why?
Proctoscopy
1
2017
1
0.160
Why?
Prostatic Diseases
1
2017
3
0.160
Why?
Digital Rectal Examination
1
2017
7
0.160
Why?
Neoplasms
1
2013
2898
0.150
Why?
Surveys and Questionnaires
4
2021
2502
0.150
Why?
Prostatic Neoplasms, Castration-Resistant
1
2019
111
0.150
Why?
Phantoms, Imaging
1
2020
429
0.150
Why?
Movement
1
2020
299
0.150
Why?
Clinical Competence
3
2021
756
0.150
Why?
Organoplatinum Compounds
1
2017
94
0.150
Why?
Immunotherapy
1
2022
631
0.150
Why?
Postoperative Care
1
2018
221
0.150
Why?
Medicare
1
2020
408
0.140
Why?
Remission Induction
1
2018
722
0.140
Why?
Ilium
1
2016
18
0.140
Why?
Organ Sparing Treatments
1
2016
38
0.140
Why?
Carcinoma, Transitional Cell
1
2018
164
0.140
Why?
Camptothecin
1
2017
189
0.140
Why?
Nephrectomy
1
2019
294
0.140
Why?
Transcriptome
1
2021
580
0.140
Why?
Internationality
1
2016
69
0.140
Why?
Sensitivity and Specificity
3
2016
1991
0.140
Why?
Reproducibility of Results
3
2017
2704
0.140
Why?
Urology
1
2017
110
0.140
Why?
Patient Safety
1
2018
211
0.140
Why?
Neutropenia
1
2016
215
0.140
Why?
Software
1
2020
653
0.130
Why?
Neoplasm Invasiveness
3
2024
552
0.130
Why?
Seminoma
1
2015
10
0.130
Why?
Orchiectomy
1
2015
68
0.130
Why?
Quality Improvement
1
2019
427
0.130
Why?
Phosphodiesterase Inhibitors
1
2014
30
0.130
Why?
Neoplasms, Germ Cell and Embryonal
1
2015
47
0.130
Why?
Drug Administration Schedule
1
2016
915
0.130
Why?
Carboplatin
1
2015
286
0.120
Why?
Skin Neoplasms
1
2019
546
0.120
Why?
Health Surveys
1
2014
239
0.120
Why?
Education, Medical, Graduate
1
2017
373
0.120
Why?
Cyclooxygenase 2 Inhibitors
1
2013
33
0.110
Why?
Radiography
2
2006
808
0.110
Why?
Kidney
1
2019
1245
0.110
Why?
Metalloporphyrins
1
2012
26
0.110
Why?
Enoxaparin
1
2012
23
0.110
Why?
Prevalence
1
2016
1240
0.110
Why?
Lower Urinary Tract Symptoms
1
2013
59
0.110
Why?
Constriction, Pathologic
1
2013
212
0.110
Why?
Diagnostic Imaging
1
2016
468
0.100
Why?
Curriculum
1
2016
542
0.100
Why?
Age Factors
3
2010
1849
0.100
Why?
Regression Analysis
2
2017
596
0.100
Why?
Longitudinal Studies
1
2014
1019
0.100
Why?
Students, Medical
1
2016
385
0.100
Why?
Proctitis
1
2010
12
0.100
Why?
Genetic Vectors
1
2012
440
0.100
Why?
Stomach Neoplasms
1
2014
266
0.100
Why?
Algorithms
2
2019
1830
0.100
Why?
Neck Dissection
2
2008
65
0.090
Why?
Radiotherapy, High-Energy
1
2010
49
0.090
Why?
Genetic Therapy
1
2012
343
0.090
Why?
Seminal Vesicles
2
2016
39
0.090
Why?
Breast Neoplasms
1
2004
2904
0.090
Why?
Registries
3
2010
703
0.090
Why?
Predictive Value of Tests
2
2006
1672
0.090
Why?
Gonadotropin-Releasing Hormone
1
2010
103
0.090
Why?
Antiviral Agents
1
2013
512
0.080
Why?
Tumor Necrosis Factor-alpha
1
2012
685
0.080
Why?
Urologic Diseases
1
2009
45
0.080
Why?
Thymidine Phosphorylase
1
2008
5
0.080
Why?
Young Adult
3
2019
5977
0.080
Why?
Vitamin B Complex
1
2008
21
0.080
Why?
Acute Disease
1
2010
827
0.080
Why?
Indium Radioisotopes
1
2007
10
0.080
Why?
Pharynx
1
2006
45
0.070
Why?
Recurrence
1
2009
1139
0.070
Why?
Iodine Radioisotopes
1
2006
134
0.070
Why?
Cisplatin
2
2024
612
0.070
Why?
Chicago
1
2009
1380
0.060
Why?
Infusions, Intravenous
1
2005
429
0.060
Why?
Palliative Care
1
2006
257
0.060
Why?
Sampling Studies
1
2004
70
0.060
Why?
Disease Management
2
2017
328
0.060
Why?
Digestive System
1
2003
42
0.060
Why?
Physics
1
2021
21
0.050
Why?
Mastectomy
1
2004
243
0.050
Why?
Androgens
1
2021
167
0.050
Why?
Patient Care Planning
1
2021
81
0.050
Why?
Perception
1
2021
168
0.050
Why?
Child, Preschool
1
2006
3612
0.040
Why?
Cell Cycle
1
2021
503
0.040
Why?
Diffusion Magnetic Resonance Imaging
1
2021
294
0.040
Why?
Retreatment
1
2019
107
0.040
Why?
Multicenter Studies as Topic
1
2019
159
0.040
Why?
Placebos
1
2019
218
0.040
Why?
Nitriles
1
2019
149
0.040
Why?
Clinical Trials, Phase II as Topic
1
2019
176
0.040
Why?
Inflammation
1
2004
926
0.040
Why?
Benzamides
1
2019
229
0.040
Why?
Aftercare
1
2019
85
0.040
Why?
Kallikreins
1
2017
47
0.040
Why?
Delphi Technique
1
2017
80
0.040
Why?
Efficiency
1
2017
38
0.040
Why?
Pelvis
1
2017
94
0.040
Why?
Radiometry
1
2016
53
0.040
Why?
Job Satisfaction
1
2017
73
0.040
Why?
Equipment Design
1
2017
406
0.040
Why?
Ultrasonography, Interventional
1
2016
121
0.030
Why?
Texas
1
2016
101
0.030
Why?
Insurance, Health
1
2017
160
0.030
Why?
Sample Size
1
2016
130
0.030
Why?
Chi-Square Distribution
1
2016
364
0.030
Why?
Odds Ratio
1
2017
679
0.030
Why?
Child
1
2006
6933
0.030
Why?
Randomized Controlled Trials as Topic
1
2019
864
0.030
Why?
Radiopharmaceuticals
1
2016
180
0.030
Why?
Double-Blind Method
1
2019
1824
0.030
Why?
Internet
1
2017
312
0.030
Why?
Educational Measurement
1
2016
226
0.030
Why?
Preoperative Period
1
2014
90
0.030
Why?
Adolescent
1
2006
8988
0.030
Why?
Image Processing, Computer-Assisted
1
2020
1205
0.030
Why?
Databases, Factual
1
2016
816
0.030
Why?
Fatigue
1
2013
175
0.030
Why?
Cell Differentiation
2
2008
1471
0.020
Why?
Health Services Accessibility
1
2014
394
0.020
Why?
Nomograms
1
2007
28
0.020
Why?
Radiation Dosage
1
2007
225
0.020
Why?
Case-Control Studies
1
2008
1809
0.010
Why?
Clinical Trials as Topic
1
2008
1169
0.010
Why?
Liauw's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (302)
Explore
_
Co-Authors (45)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_